The post-pandemic season represents a once-in-a-lifetime opportunity to transition to more sustainable and resilient health systems. Therefore, companies and governments must work in synergy and in a multilateral way.

There is no doubt that research and innovation accelerate in the presence of a cooperative network. This was demonstrated by the recent progress on anti-Covid drugs, identified in record time thanks to the extraordinary collaboration between the scientific, industrial and institutional worlds. It is now necessary to make permanent the acceleration in the development of practical solutions for silent killers such as cancer, diabetes, and heart disease, and to incentivize investments in research and development, especially those dedicated to deep-tech, which brings together biotechnology, artificial intelligence, robotics.

The B20-G20 Dialogue on Health and Life Sciences, organized by the B20 Health & Life Sciences Task Force in collaboration with the Italian Presidency of the G20, was dedicated to this theme.

The Dialogue was attended by the Italian Minister of Health Roberto Speranza, the Chair of the B20 Health & Life Sciences task force Sergio Dompé and, among others, Werner Baumann, CEO Bayer and Co-Chair of the B20 Health & Life Sciences task force; Geoff Martha, President & CEO of Medtronic and Co-Chair of the B20 Health & Life Sciences Task Force; Iskra Reic, AstraZeneca Vice President for Europe and Canada; Ulrik Knudsen, Deputy Secretary-General of the OECD; Micky Tripathi, US Department of Health National Coordinator for Health Information Technology; Budi Gunadi Sadikin, Minister of Health of Indonesia.